CFTR and cystic fibrosis: Therapeutics that target folding/trafficking mutations are known as “correctors.” On the contrary, the missense mutations, of which G551D is the most common, occurring in ∼5% of patients with CF, results in normal trafficking of a mutated CFTR channel with abnormal channel gating.